Johnson & Johnson is collaborating with the Government of India and other organizations to comprehensively address the challenge of multidrug-resistant tuberculosis (MDR-TB) in India.

**THE CHALLENGE**

In 2021, there were an estimated 2.95 million cases of TB in India. India has the highest burden of TB in the world, accounting for over a quarter (28%) of all cases worldwide. Growing resistance to commonly-used TB medicines is compounding this challenge with an estimated 119,000 cases of multidrug-resistant/ rifampicin-resistant TB (MDR/RR-TB) in 2021 more than any other country. Unfortunately, only about 58,800 patients were diagnosed, and 53,000 patients started on treatment in 2021. To build a TB-free India, it will be essential to accelerate the development and delivery of new innovations from the lab to the last mile of health to reach more patients.

**ACTION TO END TB**

The Government of India has a bold vision for a TB-free India by 2025, as outlined in its National Strategic Plan for TB Elimination. At Johnson & Johnson, we are fully committed to collaborating with the government to combat drug-resistant TB (DR-TB) and help achieve this goal.

In 2015, Johnson & Johnson introduced our medicine for MDR-TB in India, which was the first TB medicine with a novel mechanism of action to be introduced in the country in more than 40 years. From 2015-2019, we provided our MDR-TB medicine through a four-year donation program to support patient access in low- and middle-income countries (LMICs), including India. Today, our medicine is available to India and more than 135 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility (GDF). To date, 105,000 courses of medicine have been made available to India through the GDF, in addition to courses it has received through the donation program.

Additionally, Johnson & Johnson has supported efforts to strengthen healthcare delivery systems by training health workers and improving diagnostic capacity, and we are engaging youth through innovative initiatives, including 'Be the Change for TB' and MTV Nishad, to raise awareness and reduce stigma around TB at the community level, with the goal of encouraging more people to seek the care they need.

These efforts are part of a comprehensive 10-year TB initiative launched by Johnson & Johnson in September 2018 focused on enabling access to treatment regimens, finding the “missing millions” and accelerating the development of next-generation TB treatments.

**GLOBAL PROGRAM AT A GLANCE**

- **First novel medicine for TB in more than 40 years; approved in 72 countries**
- **600K+ courses of treatment delivered for MDR-TB in 158 countries, including the 30 highest-burden countries**
- **Donating 105K courses of treatment to eligible countries through a four-year donation program from 2015-2019 with USAID and JSC Pharmstandard, implemented through the Stop TB Partnership’s Global Drug Facility**


L. B. S. Marg, Mulund (West), Mumbai 400080 | Phone: 91-22-2564 4441 | Fax: 91-22-2564 3410 | CIN: U33110MH1957PTC010928 | www.jnj.in

Last updated: March 2023
COLLABORATING AT EVERY LEVEL

Johnson & Johnson is working with the Government of India and other organizations to take a holistic approach to ending TB by accelerating affordable access to treatment regimens, supporting health systems strengthening efforts, and engaging youth to raise awareness around TB to encourage health-seeking behavior.

ACCESS
Provided our MDR-TB treatment free-of-charge to patients in eligible LMICs, including India, through a four-year donation program (2015-2019); starting in 2019, have been providing access via the GDF, through which India has procured more than 105,000 courses to date.

APPROPRIATE USE
Partnered with the Revised National TB Control Program (RNTCP) to ensure safe and appropriate use of our medicine, which is critical to help prevent the emergence of antimicrobial resistance (AMR).

MEDICAL EDUCATION
Supported the training of more than 6,000 healthcare professionals in 2022 alone in the clinical management of TB and MDR-TB across ten high-burden states.

DETECTION & TESTING
From 2016-2020, funded state governments and NGOs to provide approximately 50,000 X-ray tests, 32,000 molecular tests and 4,600 pre-evaluation tests, in addition to building capacity for six culture and drug sensitivity testing labs. From 2021-2022, impacted the lives of approximately 40,000 MDR-TB patients through other programmatic interventions.

In 2021, rolled out an innovative patient finding model in high-risk urban slums through an integrated community-based approach, resulting in an improvement of case detection rates by 10x.

YOUTH EMPOWERMENT
Supported a youth-focused edutainment campaign called MTV Nishedh, in partnership with the MTV Staying Alive Foundation, that leveraged TV, radio and digital platforms to raise awareness and reduce stigma around TB, reaching a total of 35 million people. The next season of the show premiered in November 2022, featuring new TB storylines.

In March 2022, J&J India launched ‘Be the Change for TB,’ a youth-focused, digital-first precision-marketing led campaign to create youth “changemakers” for TB as part of the Company’s commitment to the Corporate TB Pledge. So far, the program has reached 55 million youth, and more than 35,000 youth have signed up as Changemakers through the initiative.

MADE IN INDIA
Partnered with Recipharm & Dishman India to locally manufacture our MDR-TB medicine for use in India and globally.

ABOUT J&J GLOBAL PUBLIC HEALTH
Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world’s most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformational products.

Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier, more equitable future.